E. Evangelista

Preclinical characterization of AB-506, an inhibitor of HBV replication targeting the viral core protein.

A. Lee, S. Majeski, A. Cuconati, 2021, Antiviral research.

Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation

Quanxin Long, N. Snead, A. Lee, 2018, Antimicrobial Agents and Chemotherapy.

High‐dose transdermal nicotine in Parkinson's disease patients: a randomized, open‐label, blinded‐endpoint evaluation phase 2 study

P. Remy, G. Fénelon, E. Audureau, 2018, European journal of neurology.

Preclinical antiviral drug combination studies utilizing novel orally bioavailable investigational agents for chronic hepatitis B infection: AB-506, a next generation HBV capsid inhibitor, and AB-452, a HBV RNA destabilizer

K. Mcclintock, S. Majeski, D. Gotchev, 2018 .